Predicting post-hepatectomy liver failure using a nomogram based on portal vein width, inflammatory indices, and the albumin-bilirubin score

Figure 1 Research flow chart. HCC: Hepatocellular carcinoma.

Figure 2 Predictive nomogram for assessing the probability of post-hepatectomy liver failure in patients with hepatocellular carcinoma. NLR: Neutrophil-to-lymphocyte ratio; PVD: Portal vein width; ALBI: Albumin-bilirubin.

Figure 3 Comparison of receiver operating characteristic curves between the nomogram and the conventional models (aspartate-to-platelet ratio index score, model for end-stage liver disease score, albumin-bilirubin score, and platelet-albumin-bilirubin score) for post-hepatectomy liver failure. A: The training set; B: The validation set. APRI: Aspartate-to-platelet ratio index; ALBI: Albumin-bilirubin; MELD: Model for end-stage liver disease; PALBI: Platelet-albumin-bilirubin

Figure 4 Calibration curve of the nomogram model. A: The training set; B: The validation set.

Figure 5 Comparison of decision curve analysis between the nomogram and the conventional models (aspartate-to-platelet ratio index score, model for end-stage liver disease score, albumin-bilirubin score, and platelet-albumin-bilirubin score) for post-hepatectomy liver failure. A: The training set; B: The validation set. APRI: Aspartate-to-platelet ratio index; ALBI: Albumin-bilirubin; MELD: Model for end-stage liver disease; PALBI: Platelet-albumin-bilirubin.